Mazdutide Peptide: Research Overview, Purity Data and Where to Buy

Most research peptides in the incretin family hit one receptor and stop there. Mazdutide doesn't. It's a synthetic analogue built on the oxyntomodulin scaffold, engineered to engage the GLP-1 receptor and the glucagon receptor at the same time, which is why the mazdutide literature reads differently from the single-target papers most labs are used to.

Real Peptides supplies research-use-only peptides and publishes lot certificates of analysis at /coas/. They're about identity, purity, counterion content, and whether the certificate on file actually matches the vial in the freezer. All products are sold for laboratory research use only and are not for human consumption.

What is mazdutide?

Mazdutide (also indexed as IBI362 and LY3305677) is a lipidated peptide analogue of oxyntomodulin that acts as a dual GLP-1 receptor and glucagon receptor agonist. Published research on mazdutide examines cardiometabolic signalling, energy expenditure pathways and hepatic glucose handling. It is supplied to laboratories as a lyophilised powder and is not an approved drug in the United States.

The common over-simplification is that mazdutide is just 'a GLP-1 peptide'. It isn't, strictly. The glucagon receptor arm is the entire design intent of the molecule, and it's what separates it from semaglutide-class compounds in both pharmacology and published endpoints. This hub covers what the molecule is, what the indexed literature examines, how laboratories handle and store it, how per-lot purity is verified, and where mazdutide can be sourced for research.

A dual agonist built on the oxyntomodulin scaffold

Mazdutide is a fatty-acid-modified peptide analogue of oxyntomodulin, a naturally occurring gut hormone that binds both the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). That dual activity is the design intent, not a side effect. Developed by Innovent Biologics under license from Eli Lilly, mazdutide carries two earlier identifiers that still dominate the older literature: IBI362 and LY3305677.

The mechanism in plain terms: GLP-1R activation in research models drives glucose-dependent insulin secretion, slows gastric emptying and engages hypothalamic satiety signalling. GCGR activation does something close to the opposite on paper. It raises hepatic glucose output, yet it also increases energy expenditure and influences hepatic lipid handling. Balancing those two arms is the pharmacological problem mazdutide was built around, and much of the published work is an exploration of where that balance lands.

The lipidation matters just as much. Attaching a fatty acid chain to a peptide backbone promotes reversible albumin binding, which slows renal clearance and extends circulating half-life. That's the structural reason mazdutide is studied on a weekly schedule in clinical research rather than a daily one.

What the published literature examines

The indexed literature on mazdutide runs from early-phase pharmacology through late-stage clinical reporting, and the full set is viewable on PubMed. Research suggests the dominant themes are cardiometabolic: glycaemic markers, body weight endpoints, hepatic fat content, lipid parameters, blood pressure, and tolerability profiles dominated by the gastrointestinal adverse events typical of the incretin class.

Here's the literature-search mistake we see constantly, and it costs people entire phases of evidence: searching only the generic name. A large share of the early mazdutide work was published while the compound was still called IBI362 or LY3305677, so a search on IBI362 returns reports that the generic-name query alone can miss. Run all three terms before concluding the evidence base is thin.

Two further characteristics shape how the mazdutide literature should be read. First, the bulk of published clinical cohorts are adults in China, which matters for external validity when comparing against multinational trial programs for other incretin peptides. Second, the trial program names, reported under the GLORY and DREAMS banners, are the fastest way to track related publications across journals.

We won't quote efficacy figures here. Trial numbers get paraphrased and distorted within two reposts, and for a research audience the primary source is the only version worth reading.

Laboratory handling and storage basics

Lyophilised mazdutide is stable as a dry powder under cold, dark, desiccated conditions, typically at or below −20°C for long-term storage, with short transit excursions at ambient temperature generally tolerated because the lyophilised state removes the water that drives hydrolysis and aggregation. Once a peptide goes into solution, that protection is gone.

In solution, standard laboratory practice for peptides in this class is refrigerated storage at 2–8°C for short working periods and −20°C or below for longer holds, protected from light. Repeated freeze-thaw cycling is the quiet killer: each cycle creates ice-crystal shear and local concentration gradients that promote aggregation, so single-use aliquots beat one repeatedly opened vial every time.

Three handling details matter more than most lab notes admit. Lipidated peptides like mazdutide are surface-active, so adsorption to glass and untreated polypropylene can quietly reduce what's actually in solution. Low-bind consumables help. Vigorous vortexing shears peptide chains and introduces air; gentle swirling until the cake dissolves is the standard. And letting a vial equilibrate to room temperature before opening prevents condensation from pulling moisture into residual powder.

No measurement arithmetic belongs on a hub page like this. Quantities used in any experiment are the researcher's call, documented against their own institutional protocols, not something a supplier should imply. Mazdutide supplied for research arrives sealed as a lyophilised powder with its lot documentation.

How purity is verified, lot by lot

Purity on a peptide certificate of analysis means one specific thing: the area-percent of the main peak on reverse-phase HPLC, usually read at 214 nm or 220 nm where the peptide bond absorbs. A mazdutide lot reported at 99% or higher HPLC purity is telling you that 99% of the UV-absorbing material eluting from that column is the target species. It is not telling you how much peptide is in the vial.

That distinction is where most sourcing decisions go wrong. Purity and net peptide content are separate measurements. A vial can be 99% pure and still hold meaningfully less peptide by mass than the label weight, because lyophilised powder also carries residual water and counterions, commonly trifluoroacetate from purification or acetate after salt exchange. Karl Fischer titration quantifies water; amino acid analysis or nitrogen determination quantifies true peptide content. Ask for both, not just the purity line.

Identity is the third leg. Mass spectrometry (ESI-MS or MALDI-TOF) confirms the observed molecular weight against the theoretical mass for the mazdutide sequence, which is what separates a correctly assembled chain from a deletion sequence that still runs clean on HPLC.

Every mazdutide lot we release ships against its own certificate, with the chromatogram and mass spectrum published rather than summarised. The certificates of analysis library is open to read before anyone commits to a lot.

Regulatory status and what research-use-only actually means

Mazdutide is not approved by the U.S. Food and Drug Administration for any indication, and it is not a dietary supplement, a compounded medicine, or a veterinary product. In the United States it moves exclusively as a research compound for in vitro and laboratory investigation. All products are sold for laboratory research use only and are not for human consumption.

Outside the U.S., mazdutide has progressed through late-stage clinical development and regulatory review in China, where Innovent Biologics has led the program. Regulatory progress in one jurisdiction does not change the status of research-grade material sold elsewhere. An approved finished drug product is manufactured, released and labelled under an entirely separate regime from research-use-only peptide supplied to a laboratory, and conflating the two is the most common misreading of mazdutide's status we encounter.

Research-use-only labelling carries obligations on the buying side too. Material is intended for qualified researchers working under appropriate institutional oversight, and handling, documentation and disposal fall under the receiving laboratory's own policies. Anyone with questions about animal health should raise them with a licensed veterinarian, because research peptides are not veterinary medicines and should never be treated as one.

The information here is educational. It describes what the published literature reports and how laboratories handle material. It is not administration guidance of any kind.

Where to buy mazdutide for laboratory research

Buying research-grade mazdutide comes down to four verifications, and price is not one of them. First, a per-lot certificate of analysis with the lot number printed on both the certificate and the vial label, because a generic representative certificate for a compound tells you nothing about the material in your freezer. Second, the raw analytical output: the HPLC chromatogram and mass spectrum, not a typed summary table. Third, synthesis transparency, since small-batch synthesis with verified amino-acid sequencing limits the lot-to-lot drift that wrecks reproducibility across a long study. Fourth, shipping practice, including insulated or cold-chain packing and a stated policy for shipments delayed in transit.

Our mazdutide product page lists the lyophilised material we supply alongside its lot documentation, and the wider peptide catalogue is organised the same way.

How dual agonists compare with single-target incretin peptides

This table maps receptor profiles and literature focus across four research peptides that get cross-compared constantly. It covers pharmacology and evidence base only, with no efficacy figures, because paraphrased trial numbers are the fastest route to a wrong conclusion.

What If: Research Sourcing Scenarios

What if a lyophilised vial arrives warm?

Record the condition on receipt and contact the supplier before opening it. Lyophilised peptides tolerate short ambient excursions far better than material in solution, because removing water removes the primary route to hydrolysis and aggregation. That tolerance isn't unlimited, and the variable that matters is time at temperature, not whether the box felt cold on arrival. A supplier who can state the pack-out method and transit duration is giving you data; one who simply says it's fine is not.

What if a certificate of analysis has no lot number?

Treat it as a marketing document rather than analytical data. A certificate is only meaningful when the lot number on it matches the number printed on the vial you received, because purity, water content and counterion residue vary batch to batch even under identical synthesis conditions. Representative certificates reused across every shipment of mazdutide tell you what a good lot once looked like, and nothing about yours. Published per-lot records exist precisely so a buyer can check before committing.

What if lot-to-lot variation shows up mid-study?

Compare certificates side by side before changing anything at the bench. Differences in net peptide content, residual water or counterion identity between mazdutide lots can shift experimental results with no change in the HPLC purity figure, which is exactly why content data matters as much as the purity line. Where a study spans months, reserving material from a single synthesis batch removes the variable entirely. Teams running long projects report that batch reservation is the cheapest reproducibility insurance available to them.

The Unglamorous Truth About Peptide Sourcing

Here's the honest answer: the quality gap between research peptide suppliers is almost never visible in the product photo, the website design, or the purity number on the label. It shows up in the paperwork. Two vials of mazdutide can both claim 99% purity, carry different net peptide content, different residual water and different counterion load, and behave differently in the same assay. The only way to see that before the experiment runs is to read the chromatogram and the content data for your specific lot. Suppliers who don't publish them usually aren't hiding anything. They just never generated the data.

Researchers comparing options across the catalogue can read the published per-lot analytics in our certificate of analysis library, browse the full research peptide range, or review how we approach high-purity synthesis before selecting a compound for a study.

Mazdutide occupies an unusual position in the research peptide world right now: a molecule with a genuinely distinct receptor profile, a clinical record concentrated in one region, and a generic name that only recently replaced the two development codes most of its early literature was filed under. That combination means the fastest way to get the science wrong is to treat it as interchangeable with the GLP-1 peptides it superficially resembles. The glucagon arm is the whole story. All products are sold for laboratory research use only and are not for human consumption.

What receptors does mazdutide activate, and what happens downstream?

Mazdutide is described in the literature as a dual agonist that binds both the glucagon-like peptide-1 receptor and the glucagon receptor, two closely related class B G protein-coupled receptors. Both couple primarily to Gs, so occupancy raises intracellular cyclic AMP and activates protein kinase A, but the tissue distribution of each receptor differs sharply. GLP-1 receptors are concentrated in pancreatic beta cells, portions of the gastrointestinal tract, and hindbrain nuclei, while glucagon receptors are most abundant in hepatocytes and adipose tissue. That split explains why researchers treat the two arms as separate experimental variables rather than a single signal, a distinction explored in more depth in the notes on GLP-1 agonism and on glucagon receptor agonism.

Because the molecule engages both receptors at once, downstream readouts rarely isolate cleanly. Hepatic glucose output, lipid handling, satiety signaling, and gastric transit can all move together in model systems, which is why study designs often include receptor-blockade or knockout arms. The combined signaling picture is laid out in the detailed mechanism overview, while tissue-level consequences are summarized in the discussion of downstream GLP-1 and glucagon effects. Material sold here is for in vitro and laboratory research only.

Why does the glucagon receptor arm matter in energy-expenditure research?

Glucagon receptor agonism is the feature that separates oxyntomodulin-derived compounds from incretin peptides that act at a single receptor. In preclinical literature, glucagon signaling in the liver is associated with increased glycogenolysis, gluconeogenesis, fatty acid oxidation, and measurable shifts in resting energy expenditure in rodent calorimetry work. Pairing that signal with GLP-1 receptor activity is the stated design rationale: the GLP-1 arm is intended to offset the glycemic consequences of glucagon receptor engagement while the glucagon arm contributes to substrate handling. Background on this balance appears in the notes on glucagon receptor agonism.

For laboratory work, the practical implication is that endpoints should be chosen on both sides of the ledger. Studies that measure only glycemic markers miss the hepatic lipid and thermogenic readouts that motivate dual agonism in the first place, a point reflected in the summaries of mechanism studies on GLP-1 and glucagon action and in the broader metabolism research overview. Receptor potency ratios differ across published dual agonists, so cross-compound comparisons require careful attention to assay conditions. Context for whole-organism endpoints is collected in the metabolic health discussion. Research use only; not for human consumption.

What is mazdutide's reported half-life, and why does it matter for study design?

Mazdutide carries a fatty acid side chain intended to promote albumin binding, the same general strategy used across several long-acting peptide agonists. Albumin association slows renal clearance and reduces enzymatic degradation, extending circulating exposure well beyond that of native oxyntomodulin, which is cleared within minutes. Published pharmacokinetic work on the compound supports a long-acting profile consistent with extended-interval study designs, and the general characteristics are summarized in the half-life notes.

For laboratory planning, elimination kinetics drive sampling schedules more than anything else. Terminal half-life determines when steady-state exposure is reached in repeat-exposure models, how long washout arms must run, and whether a single-timepoint measurement reflects peak or trough conditions. Species differences are substantial: rodent clearance is typically faster than primate clearance, so allometric assumptions should be stated explicitly rather than inferred. Absorption behavior and the fraction reaching systemic circulation in model systems are covered separately under bioavailability.

Analytical methods matter too, since LC-MS/MS quantification of an albumin-bound peptide requires validated sample preparation to avoid underreporting. Comparative kinetic data across study types are summarized in the metabolism research overview. All material referenced here is research-use-only laboratory reagent.

How do animal findings on mazdutide compare with clinical trial data?

Preclinical work on dual GLP-1/glucagon agonists generally begins with receptor binding and cAMP accumulation assays, moves to diet-induced obese rodent models, and then to larger-species pharmacokinetics. Those early studies establish receptor selectivity ratios, exposure profiles, and directional effects on body composition and hepatic lipid content. A summary of that early-stage literature is collected in the notes on animal research mechanisms and early findings.

Human trial programs ask different questions. They are powered for glycemic and body-weight endpoints, monitor gastrointestinal tolerability, and report heart rate and laboratory chemistry panels — readouts that rodent studies either cannot produce or produce in non-translatable form. Discrepancies between the two literatures are normal rather than contradictory: species differ in receptor sequence homology, clearance, baseline metabolic rate, and diet composition. The structured comparison in animal versus human research walks through where the two datasets align and where they diverge.

Researchers citing this compound should be explicit about which literature a claim comes from. Trial registries and published program summaries are tracked in the clinical trials overview, while head-to-head designs appear in the comparative studies collection. Laboratory research use only.

Why is so much mazdutide research centered on Asian study populations?

The compound was developed by a China-based biopharmaceutical company, and its largest registration trials were conducted in Chinese participants. That geography shapes the available literature in concrete ways. Body mass index thresholds defining overweight and obesity differ in Chinese and broader East Asian clinical guidance from those used in North America and Europe, so baseline populations in these trials are not directly interchangeable with Western cohorts. Background on the development pathway appears in the history section.

Beyond trial logistics, there are mechanistic reasons the distinction is discussed. Published work on East Asian metabolic phenotypes notes differences in visceral adiposity distribution and beta-cell function relative to body weight, which may influence how incretin and glucagon receptor signaling translates into measurable endpoints. Those arguments are laid out in the notes on GLP-1/glucagon mechanisms in Asian research and in the summary of key findings from Asian population research.

For a laboratory evaluating published data before designing an in vitro or animal study, the practical takeaway is to note cohort characteristics when citing effect sizes. Registry entries and ongoing study arms are indexed in the clinical trials overview. Research use only.

Is mazdutide the same compound as IBI362?

Yes — IBI362 is the development code used in early publications and trial registrations for the molecule now generally called mazdutide. The compound also appears in some literature under a licensing partner's internal designation, which is why database searches can return what look like three separate entities. Anyone building a reference list should search all identifiers to avoid missing relevant records. The naming lineage is traced in the notes on IBI362 key differences explained.

Confusion persists partly because vendors occasionally list IBI362 and mazdutide as distinct catalog items, sometimes at different stated purities. Structurally, there is no difference to report: same sequence, same lipidation strategy, same dual receptor pharmacology. Any genuine variation between vials is a manufacturing and purity question, not a molecular one, which is why analytical documentation matters more than the label. That distinction is addressed directly in the comparison of mazdutide versus IBI362.

Development-stage naming conventions and the transition from code number to international nonproprietary name are covered in the history section, and common identifier questions are answered in the FAQ. All material referenced is research-use-only and not for human consumption.

What biomarkers do laboratories track in mazdutide metabolic studies?

Study designs built around a dual GLP-1/glucagon agonist typically track markers on both signaling arms. On the incretin side, fasting glucose, glycated hemoglobin where the model permits, insulin, and C-peptide are standard. On the glucagon side, hepatic readouts dominate: alanine and aspartate aminotransferase, gamma-glutamyl transferase, and imaging- or histology-derived hepatic fat fraction in animal work. Lipid panels, including triglycerides and non-HDL cholesterol, are frequently added because fatty acid oxidation is a proposed consequence of glucagon receptor engagement. A working list is assembled in the biomarkers and metabolic tracking essentials overview.

Secondary endpoints vary by question. Energy expenditure via indirect calorimetry, respiratory exchange ratio, gastric emptying measures, and heart rate appear across the dual-agonist literature. Composite metabolic syndrome criteria are sometimes used as a single grouped endpoint, an approach discussed in the metabolic syndrome notes.

Baseline and follow-up panel selection is covered in the summary of laboratory values examined before and after study periods, and the broader endpoint framework appears in the metabolic health discussion. Reported figures should be attributed to their source study rather than generalized. Research use only; not for human consumption.

What does mazdutide research examine in hepatic steatosis and NASH models?

Hepatic fat accumulation is one of the more actively studied endpoints for GLP-1/glucagon co-agonists, because the glucagon receptor is expressed at high density on hepatocytes. The mechanistic hypothesis in the literature is that glucagon receptor signaling increases hepatic fatty acid oxidation and reduces de novo lipogenesis, while the GLP-1 arm contributes indirectly through reduced energy intake and improved glycemic handling. Published preclinical work on this class commonly uses diet-induced or methionine-choline-deficient rodent models with histological scoring of steatosis, inflammation, and fibrosis. The compound-specific literature is summarized in the NASH research overview.

Cell-based work complements the animal data. Primary hepatocyte and hepatic cell line systems are used to measure cAMP response, lipid droplet content, and transcriptional changes in oxidation and lipogenesis pathways without confounding from food intake, an approach described in the in vitro research notes.

Because liver enzymes can move for reasons unrelated to steatosis, careful studies pair biochemical markers with imaging or histology. The mechanistic framing connecting receptor activity to hepatic outcomes is laid out under downstream GLP-1 and glucagon effects and in the broader metabolism research section. Laboratory research use only.

What happens when mazdutide is studied alongside other research peptides?

Combination designs are common in metabolic peptide research, and they introduce interpretive problems worth anticipating. When two compounds act on overlapping receptor families, additive versus synergistic effects cannot be distinguished without proper factorial arms — each compound alone, both together, and vehicle. Without those arms, any observed change is uninterpretable. General considerations for multi-compound study design are collected in the notes on mazdutide combined with other peptides.

Mechanistic overlap is the first thing to check. Adding a second GLP-1 receptor agonist to a dual agonist creates competition at the same binding site rather than a new signal, while pairing with a compound acting on an unrelated pathway produces a cleaner experimental question. Pharmacokinetic interference matters too: albumin-binding peptides can compete for the same carrier capacity, altering free fraction in ways that confound exposure estimates. Known interaction considerations are summarized under interactions.

Model systems also impose limits. Certain genetic backgrounds, receptor knockouts, or disease models respond unpredictably to combined metabolic signaling, which is discussed in the contraindications notes. Cell-based screening before whole-animal work is often the more economical path, as outlined in the in vitro research overview. Research use only.

References

Peer-reviewed sources on Mazdutide indexed in PubMed, listed for research context. Real Peptides supplies Mazdutide for laboratory research use only.

1. Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials. Diabetes, obesity & metabolism, 2026. PMID 41804840. doi:10.1111/dom.70643
2. Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes, obesity & metabolism, 2026. PMID 42410325. doi:10.1111/dom.71058
3. Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Frontiers in endocrinology, 2024. PMID 38440786. doi:10.3389/fendo.2024.1309118
4. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature, 2026. PMID 41407860. doi:10.1038/s41586-025-10031-z
5. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature, 2026. PMID 41407859. doi:10.1038/s41586-025-10026-w
6. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA, 2026. PMID 42251595. doi:10.1001/jama.2026.8142
7. Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial. Contemporary clinical trials, 2026. PMID 41260459. doi:10.1016/j.cct.2025.108150
8. Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes. Expert opinion on therapeutic patents, 2026. PMID 41820018. doi:10.1080/13543776.2026.2645812